Today's Trend
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) shares moved higher after the company reached a global patent settlement with Ascendis Pharma concerning Yuviwel. The agreement removes a significant legal overhang and provides BioMarin with royalty payments on Yuviwel sales in the U.S., European Union, Brazil and South Korea.
- Patent disputes resolved: BioMarin and Ascendis agreed to end all pending global patent-related proceedings, including the U.S. International Trade Commission case. The settlement reduces litigation uncertainty and gives BioMarin an opportunity to generate royalty revenue without directly commercializing Yuviwel. BioMarin Announces Global Settlement With Ascendis Pharma
- Analyst target raised: Jefferies increased its BioMarin price target from $104 to $105 and maintained a Buy rating, implying substantial potential upside from the referenced $65.23 share price. ASND and BMRN Stocks Rise on Patent Settlement
- Mixed analyst view: HC Wainwright raised its target modestly from $59 to $60 but retained a Neutral rating, indicating that the settlement is viewed favorably but may already be reflected in the stock’s valuation. Analyst Views on BMRN
Overall, the immediate catalyst for BMRN is the removal of patent risk and the prospect of royalty income. Investors may continue to focus on the eventual size and timing of those royalties, as well as whether Yuviwel materially affects BioMarin’s competitive position and earnings outlook.